LENVIMA® (lenvatinib) is used by itself as the first treatment for a type of liver cancer called hepatocellular carcinoma (HCC) when it cannot be removed by surgery.
Inoperable liver cancer (HCC)
Another treatment choice could be part of your journey ahead
LENVIMA was studied in a clinical trial of 954 people with
previously untreated HCC that could not be removed with
surgery. In this trial, patients were randomly assigned to
receive either sorafenib or LENVIMA.
Financial assistance programs are available to help appropriate patients access LENVIMA.
Talk to your health care team to find out how you
will receive LENVIMA.